

Timor-Leste support for Pentavalent vaccine

This decision letter sets out the programme terms of a programme.

1. Country: Timor-Leste			
2. Grant number: 16-TLS-04c-X			
3. Date of decision letter: 27 November 2015			
4. Date of the partnership framework agreement: 24/01/2014			
5. Programme title: New vaccine support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme duration¹: 2012 - 2016			
9. Programme budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)			
	2012-2015	2016	Total ²
Programme budget (US\$)	US\$759,949 ³	US\$84,500	US\$844,449
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative annual amounts: (subject to the terms of the partnership framework agreement, if applicable) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2012-2015	2016	
Number of Pentavalent vaccines doses		56,500	
Number of AD syringes		47,700	
Number of re-constitution syringes		0	
Number of safety boxes		550	
Annual amounts (US\$)	US\$759,949 ⁵	US\$84,500	
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable.			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

<p>14. Co-financing obligations: Reference code: 16-TLS-04c-X-C</p> <p>According to the co-financing policy, the Country falls within the group Accelerated transition.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>	
Type of supplies to be purchased with Country funds in each year	2016
Number of vaccine doses	117,500
Number of AD syringes	98,500
Number of re-constitution syringes	
Number of safety boxes	1,100
Value of vaccine doses (US\$)	US\$165,986
Total co-financing payments (US\$) (including freight)	US\$174,000
<p>15. Operational support for campaigns: Not applicable</p>	
<p>16. Additional reporting requirements: The Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future Annual Amounts.</p>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2016
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<p>17. Financial clarifications: The Country shall provide the following clarifications to Gavi*: Not applicable</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>	
<p>18. Other conditions: Country is requested to refer to Annex A for the list of actions recommended by the Joint Appraisal and endorsed by the High Level Review Panel. The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.</p>	

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

27 November 2015